SCHEMBL19981601

SCHEMBL19981601

Cc1csc(NC(=O)/C=C/C(=O)N(C)C)n1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.55
HPGD P15428 6/20 0.55
MAPT P10636 3/20 0.55
ALDH1A1 P00352 3/20 0.55
PKM P14618 2/20 0.55
RAB9A P51151 14/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
LMNA P02545 1/20 0.49
NPC1 O15118 10/20 0.49
POLB P06746 2/20 0.49
RECQL P46063 1/20 0.47
KDM4E B2RXH2 2/20 0.45
GAA P10253 2/20 0.45
TP53 P04637 1/20 0.45
HTT P42858 1/20 0.45
HSD17B10 Q99714 1/20 0.45
RCE1 Q9Y256 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19981604 0.85 SMN1; SMN2 (0.52) SMN1; SMN2HPGDMAPTALDH1A1PKM
SCHEMBL19974119 0.83 SMN1; SMN2 (0.59) SMN1; SMN2HPGDMAPTALDH1A1PKM
SCHEMBL19974118 0.83 SMN1; SMN2 (0.59) SMN1; SMN2HPGDMAPTALDH1A1PKM
SCHEMBL30823702 0.82 SMN1; SMN2 (0.58) SMN1; SMN2HPGDMAPTALDH1A1PKM
SCHEMBL11492869 0.78 MAPT (0.60) SMN1; SMN2HPGDMAPTALDH1A1PKM
SCHEMBL19981418 0.77 MAPT (0.64) SMN1; SMN2HPGDMAPTALDH1A1PKM
SCHEMBL23647322 0.75 RAB9A (0.62) SMN1; SMN2HPGDMAPTALDH1A1PKM
SCHEMBL1691061 0.73 MAPT (0.68) SMN1; SMN2HPGDMAPTALDH1A1RAB9A
SCHEMBL10816647 0.73 RAB9A (0.71) SMN1; SMN2HPGDMAPTALDH1A1RAB9A
SCHEMBL19994395 0.72 MAPT (0.66) SMN1; SMN2HPGDMAPTALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3512602-B1 INHIBITORS OF HEAT SHOCK FACTORS (HSF) AND USES THEREOF HSF PHARMACEUTICALS (CH) 2024-03-27 EP disclosed
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2023-03-07 US disclosed
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2023-03-07 US disclosed
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF PHARMACEUTICALS SA (CH) 2021-07-22 US disclosed
WO-2018050656-A2 INHIBITORS OF HEAT SHOCK FACTORS AND USES THEREOF HSF PHARMACEUTICALS (CH) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597708-B2 Inhibitors of heat shock factors and uses thereof HSF1, HSP90AB2P, HSP90AB1 SMN1; SMN2 4284/4885HPGD 795/4885MAPT 2930/4885
US-20210221778-A1 Inhibitors of heat shock factors and uses thereof HSF1, HSP90AB2P, HSP90AB1 SMN1; SMN2 4284/4885HPGD 795/4885MAPT 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.